InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:11 February 2022

Olema: This Phase I trial is seeking to determine the recommended dose, safety and tolerability of a new hormone therapy (OP-1250) in combination with targeted therapy (palbociclib) in people with advanced or metastatic HR+ and HER2- breast cancerA Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer

Clinical summary

Summary

This study consists of two parts: Part 1 Dose Escalation, and Part 2 Dose Expansion. In Part 1, participants will be allocated to receive different dosage levels of OP-1250 and this will be administered (orally) once daily in continuous 28-day cycles, in combination with oral palbociclib (125mg) once daily for 21 days in continuous 28-day cycles. Participants will continue to receive treatment at the assigned dose level, or at a reduced dose if required based on any toxicities that occur. Part 2 further explores the safety and Pharmacokinetics of OP-1250 in combination with Palbociclib and to determine the recommended Phase II dose (RP2D) of OP-1250.

Age

People18+

Phase

I

Trial Acronym

Olema

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Olema Pharmaceuticals, Inc.

Scientific Title

A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer

Eligibility

Inclusion

  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.

Exclusion

  • You are able to swallow medication by mouth.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more